Logo image of VRAX

VIRAX BIOLABS GROUP LTD (VRAX) Stock Fundamental Analysis

USA - NASDAQ:VRAX - KYG9495L1251 - Common Stock

0.6133 USD
-0.01 (-2.26%)
Last: 9/26/2025, 8:00:02 PM
0.6186 USD
+0.01 (+0.86%)
After Hours: 9/26/2025, 8:00:02 PM
Fundamental Rating

2

VRAX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 101 industry peers in the Health Care Providers & Services industry. While VRAX seems to be doing ok healthwise, there are quite some concerns on its profitability. VRAX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year VRAX has reported negative net income.
In the past year VRAX has reported a negative cash flow from operations.
VRAX had negative earnings in each of the past 5 years.
VRAX had a negative operating cash flow in each of the past 5 years.
VRAX Yearly Net Income VS EBIT VS OCF VS FCFVRAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 -2M -4M -6M

1.2 Ratios

Looking at the Return On Assets, with a value of -94.31%, VRAX is doing worse than 96.04% of the companies in the same industry.
The Return On Equity of VRAX (-106.41%) is worse than 77.23% of its industry peers.
Industry RankSector Rank
ROA -94.31%
ROE -106.41%
ROIC N/A
ROA(3y)-90.9%
ROA(5y)-1063.54%
ROE(3y)-97.23%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VRAX Yearly ROA, ROE, ROICVRAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VRAX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VRAX Yearly Profit, Operating, Gross MarginsVRAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025 0 -20K -40K -60K -80K

More info and screens

5

2. Health

2.1 Basic Checks

VRAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VRAX has more shares outstanding
VRAX has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, VRAX has a worse debt to assets ratio.
VRAX Yearly Shares OutstandingVRAX Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
VRAX Yearly Total Debt VS Total AssetsVRAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M

2.2 Solvency

Based on the Altman-Z score of 1.03, we must say that VRAX is in the distress zone and has some risk of bankruptcy.
VRAX's Altman-Z score of 1.03 is on the low side compared to the rest of the industry. VRAX is outperformed by 70.30% of its industry peers.
VRAX has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
VRAX has a better Debt to Equity ratio (0.06) than 79.21% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z 1.03
ROIC/WACCN/A
WACC10.44%
VRAX Yearly LT Debt VS Equity VS FCFVRAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 5M -5M

2.3 Liquidity

VRAX has a Current Ratio of 7.27. This indicates that VRAX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 7.27, VRAX belongs to the top of the industry, outperforming 97.03% of the companies in the same industry.
A Quick Ratio of 7.13 indicates that VRAX has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 7.13, VRAX belongs to the best of the industry, outperforming 97.03% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.27
Quick Ratio 7.13
VRAX Yearly Current Assets VS Current LiabilitesVRAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 50.82% over the past year.
Looking at the last year, VRAX shows a very negative growth in Revenue. The Revenue has decreased by -95.91% in the last year.
VRAX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -42.47% yearly.
EPS 1Y (TTM)50.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.62%
Revenue 1Y (TTM)-95.91%
Revenue growth 3YN/A
Revenue growth 5Y-42.47%
Sales Q2Q%-98.25%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
VRAX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.04% yearly.
EPS Next Y166.67%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year66.97%
Revenue Next 2Y-29.64%
Revenue Next 3Y-4.67%
Revenue Next 5Y16.04%

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VRAX Yearly Revenue VS EstimatesVRAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5M 10M 15M 20M 25M
VRAX Yearly EPS VS EstimatesVRAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 0 -0.05 -0.1 -0.15

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

VRAX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 15.03, the valuation of VRAX can be described as correct.
Compared to the rest of the industry, the Price/Forward Earnings ratio of VRAX indicates a somewhat cheap valuation: VRAX is cheaper than 75.25% of the companies listed in the same industry.
VRAX's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.89.
Industry RankSector Rank
PE N/A
Fwd PE 15.03
VRAX Price Earnings VS Forward Price EarningsVRAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VRAX Per share dataVRAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 -1.5

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

VRAX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIRAX BIOLABS GROUP LTD

NASDAQ:VRAX (9/26/2025, 8:00:02 PM)

After market: 0.6186 +0.01 (+0.86%)

0.6133

-0.01 (-2.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A N/A
Earnings (Next)12-13 2022-12-13/bmo
Inst Owners6.06%
Inst Owner ChangeN/A
Ins Owners9.73%
Ins Owner ChangeN/A
Market Cap2.66M
AnalystsN/A
Price TargetN/A
Short Float %9%
Short Ratio0.53
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 15.03
P/S 415.89
P/FCF N/A
P/OCF N/A
P/B 0.47
P/tB 0.47
EV/EBITDA N/A
EPS(TTM)-1.65
EYN/A
EPS(NY)0.04
Fwd EY6.65%
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)-1.05
OCFYN/A
SpS0
BVpS1.31
TBVpS1.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -94.31%
ROE -106.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-90.9%
ROA(5y)-1063.54%
ROE(3y)-97.23%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 175.86%
Cap/Sales 9435.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.27
Quick Ratio 7.13
Altman-Z 1.03
F-Score2
WACC10.44%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)4134.9%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.62%
EPS Next Y166.67%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-95.91%
Revenue growth 3YN/A
Revenue growth 5Y-42.47%
Sales Q2Q%-98.25%
Revenue Next Year66.97%
Revenue Next 2Y-29.64%
Revenue Next 3Y-4.67%
Revenue Next 5Y16.04%
EBIT growth 1Y-0.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year161.03%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.95%
OCF growth 3YN/A
OCF growth 5YN/A